AbbVie in charts: Revenues from Humira -55%, Skyrizi +47%, Rinvoq +35% Y/Y

More on AbbVie

• AbbVie: Deep Discount Before Earnings
• AbbVie: "Strong Buy" On Rinvoq Expansions And Immunology Pipeline Addition
• AbbVie: Wins Accumulating While We Wait For Next BD Steps
• AbbVie Non-GAAP EPS of $1.86 beats by $0.08, revenue of $15.78B beats by $200M
• AbbVie Q3 Earnings Preview: R&D charge impact, pipeline progress in focus